Posted on

blueberry stock

Blueberries Medical Corp. (CSE:BBM) (BBRRF) (1OA.F) (the “Company” or “Blueberries”), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Ministry of Justice and Law of the Republic of Colombia has granted a non-psychoactive cultivation license for the Zipaquira property, making it the Company’s second fully licensed cultivation facility in Colombia. The granted license brings Blueberries closer to being one of larger licensed medicinal cannabis producers for domestic and international distribution. In order to quickly and cost-effectively bring the Zipaquira property into production, the Company has signed a Letter of Intent (“LOI”) to enter into a joint venture with QualCann SAS (“QualCann”) for the development of the property into a low-cost outdoor cultivation facility.
Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or “Blueberries”), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Company has partnered with the Van Uden International Center for Alternative Medicine (“Van Uden”) and the Juan N. Corpas University Foundation (the “Foundation”), two renowned Colombian organizations in the health and academic fields. The partnerships will facilitate the distribution of Blueberries’ products to a patient network of over 12,000 and bridge the gap between research and clinical practice by educating physicians on the applications and benefits of medicinal cannabis treatments.
Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or “Blueberries”), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce it has closed its over-subscribed, non-brokered private placement (the “Offering”) of units (the “Units”) at a price of CBlueberries Medical Corp. (CSE: BBM) (BBRRF) (1OA.F) (“Blueberries” or the “Company”), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Company’s common shares, traded in the United States under the symbol BBRRF, are now eligible for electronic clearing and settlement through the Depository Trust Company in the United States. Dr. Patricio Stocker, CEO of Blueberries commented: “DTC eligibility will allow current and prospective Blueberries shareholders more reliable, cost-efficient, and timely clearing and settlement for our common shares..25 per Unit for total gross proceeds of C$3,457,500. Each Unit consists of one common share in the capital of the Company (a “Share”) and one Share purchase warrant (a “Warrant”). This is an exciting time of growth for the company and this capital will allow us to invest in and scale our business effectively,” stated Dr. Patricio Stocker, Chief Executive Officer.
Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or “Blueberries”), a leading Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce the formation of its medical & scientific committee to support management in the development of leading-edge formulations as well as its ongoing commercial and educational initiatives. Leveraging their unique and collective expertise in the healthcare industry in South and North America, the Blueberries medical & scientific committee is focused on the development of innovative formulations to treat specific pathologies, as well as safe and effective treatment regimes.
Blueberries has commissioned the first extraction line at its 2,800 m2 (30,138 ft2) state-of-the-art extraction facility, strategically located in Cundinamarca, the region with the highest concentration of licensed cannabis producers. The first extraction line is fully operational and located in a modern and secure industrial park 30 minutes outside of Bogota.
Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or “Blueberries”), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that it has commenced harvest of its first commercial crops at its 3.2-hectare Guatavita facility located in Bogotá Savannah, Colombia. The crops consist of the Company’s five registered non-psychoactive cannabidiol (“CBD”) strains recently approved by the Colombian Institute of Agriculture (“ICA”), as announced on September 27, 2019.
This is the first of a two-part series on the history of Colombia and its route to cannabis legalization. Colombia is in an extraordinary position. It possesses the fourth largest economy in Latin America.
Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or “Blueberries”), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Board of Directors has appointed Mr. Camilo Villalba as Chief Executive Officer of the Company. Mr. Villalba, who is a co-founder of Blueberries and currently serves as Chief Operating Officer, will lead the Company’s next phase of operational development, with initial exports expected during the first half of 2020.
Blueberries Medical Corp. (BBM.CN) (BBRRF) (1OA.F) (the “Company” or “Blueberries”), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Company has received approval from the Colombian Institute of Agriculture (“ICA”) for the registration of five proprietary non-psychoactive cannabidiol (CBD) strains with the national cultivar registry and to commence commercial production of these strains. The registration and approval to commence commercial production is amongst the first to be issued in Colombia and a major milestone for the Company.
Find the latest BLUEBERRIES MEDICAL CORP (BBRRF) stock quote, history, news and other vital information to help you with your stock trading and investing.